Spero Therapeutics, Inc. (SPRO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q3 '21: 3.1M Q4 '21: 2.7M Q1 '22: 2.1M Q2 '22: 2M Q3 '22: 2M Q4 '22: 47.4M Q1 '23: 2.1M Q2 '23: 2.7M Q3 '23: 25.5M Q4 '23: 73.5M Q1 '24: 9.3M Q2 '24: 10.2M Q3 '24: 13.5M Q4 '24: 15M Q1 '25: 5.9M Q2 '25: 14.2M Q3 '25: 5.4M Q4 '25: 41.3M Q1 '26: 258K Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-40M -20M 0 20M 40M 60M Q3 '21: -22.5M Q4 '21: -27.5M Q1 '22: -30.2M Q2 '22: -26.1M Q3 '22: -11.8M Q4 '22: 25.9M Q1 '23: -14.2M Q2 '23: -12.9M Q3 '23: -1.9M Q4 '23: 50.5M Q1 '24: -14M Q2 '24: -19.1M Q3 '24: -18.6M Q4 '24: -21.7M Q1 '25: -14.7M Q2 '25: -2.4M Q3 '25: -7.9M Q4 '25: 31.4M Q1 '26: -7.5M Q2 '26: -9.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '21: -19.4M Q2 '21: -18.6M Q3 '21: -22.5M Q4 '21: -29.3M Q1 '22: -32.8M Q2 '22: -28.7M Q3 '22: -11.7M Q4 '22: 26.8M Q1 '23: -13.3M Q2 '23: -11.9M Q3 '23: -3.2M Q1 '24: -12.7M Q2 '24: -17.9M Q3 '24: -17.1M Q4 '24: -20.9M Q1 '25: -13.9M Q2 '25: -1.7M Q3 '25: -7.4M Q1 '26: -7.2M Q2 '26: -9.6M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q3 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q3 '21: -5M Q4 '21: -27.3M Q1 '22: -28.2M Q2 '22: -23M Q3 '22: -957K Q4 '22: 44.5M Q1 '23: -12.9M Q2 '23: -18.6M Q3 '23: 15.9M Q4 '23: -17.5M Q1 '24: 5.9M Q2 '24: -18.7M Q3 '24: 12.8M Q4 '24: -23.4M Q1 '25: -4M Q2 '25: -17.7M Q3 '25: 17.4M Q4 '25: -8.4M Q1 '26: 15.9M Q2 '26: -5.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q4 '16: -9.5M Q4 '18: -15.9M Q1 '19: -11M Q2 '19: -12.2M Q3 '19: -9.7M Q4 '19: -17.5M Q1 '20: -23.4M Q2 '20: -24.9M Q3 '20: -21.3M Q4 '20: -16.4M Q3 '21: -5M Q4 '16 Q1 '19 Q3 '19 Q1 '20 Q3 '20 Q3 '21

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '21: 29.7M Q3 '21: 32.1M Q1 '22: 32.6M Q2 '22: 33M Q3 '22: 35.9M Q1 '23: 52.5M Q2 '23: 52.6M Q3 '23: 52.7M Q1 '24: 53.5M Q2 '24: 54M Q3 '24: 54.1M Q1 '25: 55.4M Q2 '25: 56M Q3 '25: 56.3M Q1 '26: 57.3M Q2 '26: 58M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '19: -3.29 Q1 '20: -4.22 Q2 '20: -4.33 Q3 '20: -4.24 Q4 '20: -3.54 Q1 '21: -2.98 Q2 '21: -2.76 Q3 '21: -2.60 Q4 '21: -2.91 Q1 '22: -3.26 Q2 '22: -3.50 Q3 '22: -3.13 Q4 '22: -1.23 Q1 '23: -0.47 Q2 '23: 0.17 Q3 '23: 0.44 Q4 '24: -1.27 Q1 '25: -1.28 Q2 '25: -0.98 Q3 '25: -0.79 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.